SL-28 for Advanced Solid Tumours (NCT07341737) | Clinical Trial Compass
RecruitingPhase 1/2
SL-28 for Advanced Solid Tumours
Australia60 participantsStarted 2026-07-13
Plain-language summary
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since SL-28 is being tested in a Phase 1/2 trial and the primary goal is to figure out safe doses and identify side effects — not yet to prove it works — what does that mean for my personal risk if I were to consider enrolling?
2The trial is specifically watching for 'dose-limiting toxicities' in the first 28 days after infusion and monitoring heart rhythm changes like QT interval — given my current heart health and overall condition, are those the kinds of risks my care team would be most concerned about for me?
3My cancer type is one of many being studied here alongside very different cancers like pancreatic, bladder, and melanoma — does that broad eligibility tell us anything about how much is already known about how SL-28 might work for my specific diagnosis?
4Before looking at an early-phase trial like this, are there standard treatments or other more established clinical trials that my care team would recommend I try first, and what would it mean for my options if I enrolled in this study now?
5Since participants receive SL-28 by infusion and are closely monitored for safety events, how frequently would I need to come in for visits during that critical first 28-day window, and is that schedule realistic given my current situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of participants with treatment-emergent adverse events
Timeframe: 12 weeks
2
To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.
Timeframe: 12 weeks
3
Change from baseline in ECG QT interval
Timeframe: 12 weeks
4
Change from baseline in vital signs
Timeframe: 12 weeks
5
Change from baseline in vital signs
Timeframe: 12 weeks
6
Change from baseline in vital signs
Timeframe: 12 weeks
7
Number of participants with dose-limiting toxicities (DLTs)